Drug intelligence / Profile preview

DW-3102

Development stage: Phase 2
Lead developer: Daewon Pharm

Overview

DW-3102 is an investigational drug developed by Daewon Pharmaceutical for the treatment of hypercholesterolemia. It has reached Phase 2 clinical trials, where its adequate dose and safety profile were evaluated in patients with hypercholesterolemia. The specific mechanism of action, molecular target, and modality have not been publicly disclosed as of June 2025. There is no evidence that it has received regulatory approval or advanced beyond Phase 2 trials[1][3][4][9].

Beyond the preview

Go deeper on DW-3102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-3102.

Explore the full profile